儿童肿瘤中医使用的模式:系统综述、荟萃分析与数据挖掘
在白血病患者中,常规治疗加用中医显著提高临床缓解率(OR=2.55, 95%CI 1.49-4.36)、降低感染率(OR=0.23, 95%CI 0.13-0.40)并减少恶心呕吐(OR=0.13, 95%CI 0.08-0.23)。
要点
- 儿童肿瘤中医辅助治疗以血液恶性肿瘤研究为主,多数随机对照试验关注化疗毒性。
- 白血病患者常规治疗加中医可提高缓解率、降低感染率并减少恶心呕吐。
- 黄芪是最常用中药(58.0%),与治疗骨髓抑制、胃肠道并发症和感染相关。
核心结论
- 越来越多的证据表明中医是儿童肿瘤的有效辅助治疗。
- 提出了一份清单以改善儿童肿瘤中医试验的质量。
研究设计与样本
- 纳入随机对照试验或观察性临床研究,对象为年龄<19岁确诊癌症的患者,且至少一组接受中医治疗。
- 共纳入54项研究,其中随机对照试验占63.0%,观察性研究占37.0%。
主要发现
- 大多数随机对照试验关注血液恶性肿瘤(41.2%),结局包括化疗所致毒性(76.5%)、感染率(35.3%)以及缓解、生存或复发率(23.5%)。
- 大多数随机对照试验(82.4%)和观察性研究(80.0%)的方法学质量被评为「中等」。
- 在白血病患者中,常规治疗加用中医显著提高临床缓解率(OR=2.55; 95%CI=1.49-4.36)。
- 在白血病患者中,常规治疗加用中医显著降低感染率(OR=0.23; 95%CI=0.13-0.40)并减少恶心呕吐(OR=0.13; 95%CI=0.08-0.23)。
- 关联规则挖掘显示黄芪是最常用中药(58.0%),与治疗骨髓抑制、胃肠道并发症和感染相关。
临床怎么用
- 在儿童白血病常规治疗中可考虑联合中医辅助治疗以改善缓解率并减少感染和恶心呕吐。
- 关注黄芪在骨髓抑制、胃肠道并发症和感染管理中的潜在应用。
- 儿童肿瘤中医临床研究设计可参考本文提出的清单以提高质量。
局限性
- 多数纳入研究的方法学质量仅为「中等」,可能影响结论可靠性。
- 未来需在真实世界数据中运用关联规则挖掘技术评估中药疗效及药物-中药相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Traditional Chinese medicine (TCM) is becoming a popular complementary approach in pediatric oncology. However, few or no meta-analyses have focused on clinical studies of the use of TCM in pediatric oncology. OBJECTIVE: We explored the patterns of TCM use and its efficacy in children with cancer, using a systematic review, meta-analysis and data mining study. SEARCH STRATEGY: We conducted a search of five English (Allied and Complementary Medicine Database, Embase, PubMed, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov) and four Chinese databases (Wanfang Data, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and VIP Chinese Science and Technology Periodicals Database) for clinical studies published before October 2021, using keywords related to "pediatric," "cancer," and "TCM." INCLUSION CRITERIA: We included studies which were randomized controlled trials (RCTs) or observational clinical studies, focused on patients aged < 19 years old who had been diagnosed with cancer, and included at least one group of subjects receiving TCM treatment. DATA EXTRACTION AND ANALYSIS: The methodological quality of RCTs and observational studies was assessed using the six-item Jadad scale and the Effective Public Healthcare Panacea Project Quality Assessment Tool, respectively. Meta-analysis was used to evaluate the efficacy of combining TCM with chemotherapy. Study outcomes included the treatment response rate and occurrence of cancer-related symptoms. Association rule mining (ARM) was used to investigate the associations among medicinal herbs and patient symptoms. RESULTS: The 54 studies included in this analysis were comprised of RCTs (63.0%) and observational studies (37.0%). Most RCTs focused on hematological malignancies (41.2%). The study outcomes included chemotherapy-induced toxicities (76.5%), infection rate (35.3%), and response, survival or relapse rate (23.5%). The methodological quality of most of the RCTs (82.4%) and observational studies (80.0%) was rated as "moderate." In studies of leukemia patients, adding TCM to conventional treatment significantly improved the clinical response rate (odds ratio [OR] = 2.55; 95% confidence interval [CI] = 1.49-4.36), lowered infection rate (OR = 0.23; 95% CI = 0.13-0.40), and reduced nausea and vomiting (OR = 0.13; 95% CI = 0.08-0.23). ARM showed that Radix Astragali, the most commonly used medicinal herb (58.0%), was associated with treating myelosuppression, gastrointestinal complications, and infection. CONCLUSION: There is growing evidence that TCM is an effective adjuvant therapy for children with cancer. We proposed a checklist to improve the quality of TCM trials in pediatric oncology. Future work will examine the use of ARM techniques on real-world data to evaluate the efficacy of medicinal herbs and drug-herb interactions in children receiving TCM as a part of integrated cancer therapy.
引用
- Lam CS, Peng LW, Yang LS, et al. Examining patterns of traditional Chinese medicine use in pediatric oncology: A systematic review, meta-analysis and data-mining study. J Integr Med. 2022. PMID: 35750623. doi:10.1016/j.joim.2022.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。